We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

ThromboGenics Announces that Microplasmin Meets Primary Endpoint in Phase III Trial for VMA

News   Apr 26, 2010

 
ThromboGenics Announces that Microplasmin Meets Primary Endpoint in Phase III Trial for VMA
 
 
Advertisement
 

RELATED ARTICLES

Russia’s COVID-19 Vaccine “Approved for Mass Production” Despite No Phase III Data

News

The scientific community has been left somewhat perplexed today after Russian President Vladamir Putin announced that Russian authorities have approved the world's first COVID-19 vaccine.

READ MORE

Team Develops Synthetic Blood-Thinner With No Bleeding Side Effects

News

Scientists have developed a highly selective and highly stable synthetic blood-thinning molecule that, unlike others, doesn’t cause bleeding adverse effects.

READ MORE

RLF-100 Trial Shows Rapid Recovery From Respiratory Failure in Critically Ill Patients With COVID-19

News

A clinical trial of RLF-100 (aviptadil) has shown rapid recovery from respiratory failure in critically ill patients with COVID-19.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE